DNA Biomed Solns (DNA) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.003x

Based on the latest financial reports, DNA Biomed Solns (DNA) has a cash flow conversion efficiency ratio of -0.003x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-265.00K ≈ $-710.46 USD) by net assets (ILA82.79 Million ≈ $221.96K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DNA Biomed Solns market capitalisation for the company's overall valuation and market capitalisation.

DNA Biomed Solns - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how DNA Biomed Solns's cash flow conversion efficiency has evolved over time, based on yearly financial data.

DNA Biomed Solns Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DNA Biomed Solns ranked by their cash flow conversion efficiency. Explore DNA Biomed Solns earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Hotel Fitra International Tbk PT JK:FITT	-0.096x
Binh Duong Trade and Development JSC VN:TDC	0.212x
Viomi Technology ADR NASDAQ:VIOT	-0.320x
Red Metal Ltd AU:RDM	-0.124x
Filana Therapeutics, Inc. NASDAQ:FLNA	-0.061x
Myomo Inc NYSE MKT:MYO	-0.244x
Youlife Group Inc. American Depositary Shares NASDAQ:YOUL	N/A
Cpt Drives & Power Pcl BK:CPT	-0.152x

Annual Cash Flow Conversion Efficiency for DNA Biomed Solns (2013–2024)

The table below shows the annual cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024. View DNA stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA101.47 Million ≈ $272.02K	ILA1.61 Million ≈ $4.32K	0.016x	+285.32%
2023-12-31	ILA79.19 Million ≈ $212.30K	ILA-678.00K ≈ $-1.82K	-0.009x	-93.75%
2022-12-31	ILA80.11 Million ≈ $214.76K	ILA-354.00K ≈ $-949.06	-0.004x	+89.70%
2021-12-31	ILA54.33 Million ≈ $145.66K	ILA-2.33 Million ≈ $-6.25K	-0.043x	+44.17%
2020-12-31	ILA7.95 Million ≈ $21.32K	ILA-611.00K ≈ $-1.64K	-0.077x	-57.74%
2019-12-31	ILA28.18 Million ≈ $75.56K	ILA-1.37 Million ≈ $-3.68K	-0.049x	-90.35%
2018-12-31	ILA64.90 Million ≈ $174.00K	ILA-1.66 Million ≈ $-4.45K	-0.026x	+7.16%
2017-12-31	ILA69.11 Million ≈ $185.27K	ILA-1.91 Million ≈ $-5.11K	-0.028x	-116.08%
2016-12-31	ILA-83.41 Million ≈ $-223.63K	ILA-14.30 Million ≈ $-38.34K	0.171x	-90.81%
2015-12-31	ILA-8.35 Million ≈ $-22.38K	ILA-15.57 Million ≈ $-41.73K	1.865x	+41.84%
2014-12-31	ILA-8.36 Million ≈ $-22.40K	ILA-10.99 Million ≈ $-29.45K	1.315x	+391.99%
2013-12-31	ILA11.49 Million ≈ $30.80K	ILA-5.17 Million ≈ $-13.87K	-0.450x	--

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$32.85 Million

ILA12.25 Billion ILA

Market Cap Rank

#23522 Global

#326 in Israel

Share Price

ILA99.50

Change (1 day)

-2.45%

52-Week Range

ILA86.00 - ILA147.50

All Time High

ILA1900.80